Showing results (11-20 of 28) with videos related to

Sort By:
Pageof 3
Frontiers in Oncology|April 27, 2026
Clinical implementation of a one-step no-wash flow cytometry method allows for real-time monitoring of patients treated with autologous CAR-T cellsNassim Salem, Clémence Demerlé, Bechara Mfarrej, et al.
Cancer Treatment Reviews|March 29, 2025
Pharmacology and pharmacokinetics of antibody-drug conjugates, where do we stand?Arthur Géraud, Paul Gougis, Alexandre de Nonneville, et al.
Cancer Discovery|March 20, 2023
Tracing Founder Mutations in Circulating and Tissue-Resident Follicular Lymphoma PrecursorsJoseph G Schroers-Martin, Joanne Soo, Gabriel Brisou, et al.
Bone Marrow Transplantation|June 6, 2026
Impact of fludarabine dosage on outcomes in large B-cell lymphoma patients treated with CAR T-cell therapy: a retrospective study of the CTIWP of the EBMTGuillaume Dachy, Jarl E Mooyaart, Ludovic Gabellier, et al.
Clinical Nuclear Medicine|June 11, 2021
Prognostic Impact of 18F-FDG PET/CT in Patients With Aggressive B-Cell Lymphoma Treated With Anti-CD19 Chimeric Antigen Receptor T CellsPierre Sesques, Jérémie Tordo, Emmanuelle Ferrant, et al.
Hemasphere|February 19, 2025
Outcomes of patients with relapsed or refractory primary mediastinal B-cell lymphoma treated with anti-CD19 CAR-T cells: CARTHYM, a study from the French national DESCAR-T registryJean Galtier, Charles Mesguich, Pierre Sesques, et al.
Blood Advances|January 9, 2026
Health-related quality of life after second-line Axi-cel in transplant-ineligible patients with large B-cell lymphomaEmilie Charton, Amélie Anota, Emmannuel Bachy, et al.
Haematologica|May 15, 2025
Clinical benefit of tafasitamab plus lenalidomide in relapsed or refractory diffuse large Bcell lymphoma: real-world data from the EarlyMIND studyGabriel Brisou, Jérôme Paillassa, Sophie Bernard, et al.
Nature Medicine|September 14, 2023
Axicabtagene ciloleucel as second-line therapy in large B cell lymphoma ineligible for autologous stem cell transplantation: a phase 2 trialRoch Houot, Emmanuel Bachy, Guillaume Cartron, et al.
Blood Advances|September 18, 2025
Poor Outcomes with BCMA-targeting bispecific antibodies following early relapse from ide-cel: a real-world French studySarah Cayla, Lionel Karlin, Jerome Lambert, et al.
Pageof 3